14/05/2026
Big shift in women's health.
The Lancet has just published a landmark consensus paper proposing that PCOS be renamed PMOS - Polyendocrine Metabolic
Ovarian Syndrome.
This isn't a cosmetic change.
It's a correction of the story we've been telling for far too long.
PCOS has always been more than an ovarian issue.
It's a multisystem endocrine and metabolic condition - affecting insulin, androgens, neuroendocrine function, metabolism, mood, fertility, and long-term health.
The name PCOS has:
ร Implied it's just about cysts (it's not)
X Hidden the metabolic and endocrine drivers
ร Contributed to delayed diagnosis
ร Added to stigma and fragmentation of care
ร Limited research and policy attention
The new proposed name - PMOS - is more accurate. More inclusive. More aligned with the lived experience of millions of women.
The paper also recognises that AMH can now be used as an alternative marker of ovarian morphology alongside ultrasound in adults - but diagnosis still relies on a combination of features.
This is the evolution we've been waiting for.
Language shapes diagnosis.
Diagnosis shapes care.
Care shapes outcomes.
Proud to be part of a movement that's advocating for science, for women, and for a healthcare system that finally sees the whole picture. PCOS is also part of a wider conversation around neurodivergence, burnout, executive function, and womenโs mental health.
This conversation also intersects with neurodivergence - because many of these women experience overlapping challenges of ADHD/Autism/ AuDHD with their executive function, mood, sensory overwhelm, and burnout that traditional siloed care has often missed.
We're not just changing the name.
We're changing the future.
NeuroHormone Hub
